<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01391845</url>
  </required_header>
  <id_info>
    <org_study_id>ist1979</org_study_id>
    <nct_id>NCT01391845</nct_id>
  </id_info>
  <brief_title>Ulipristal Acetate on Progesterone Levels and Glycodelin-A Endometrial Pattern</brief_title>
  <official_title>Effect of Ulipristal Acetate Administration on Serum Progesterone Levels and Glycodelin-A Endometrial Pattern in Women Undergoing Controlled Ovulation Stimulation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Programa de Asistencia Reproductiva de Rosario</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Programa de Asistencia Reproductiva de Rosario</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Controlled ovarian stimulation (COS) for FIV increases progesterone (P) and estradiol (E2)
      serum levels in supraphysiologic concentrations at the end of follicular phase. Elevated
      serum P levels leads to an accelerated endometrial maturation which interferes with the
      dialogue between embryo and endometrium. It has been reported that serum progesterone levels
      ≥ 1.5 ng/ml on the last day of COS are related to a significant decrease in the ongoing
      pregnancy rate following IVF cycles. Also, it has been reported a significant alteration in
      the endometrial gene expression profile related to P elevated levels.

      Glycodelin-A is an immunomodulatory glycoprotein synthesized by luteal-phase endometrial
      epithelium and its expression seems to be related to the action of P. Because glycodelin-A
      has immunosuppressive activity, it may facilitate the process of implantation and the
      maintenance of pregnancy.

      It is already know that ulipristal acetate (UPA) decrease serum P levels. The hypothesis of
      this study is that UPA is been able to modify P serum levels and glycodelin-A endometrial
      expression pattern on FSH/GnRH Antagonist cycles for FIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Controlled ovarian stimulation (COS) for FIV increases progesterone (P) and estradiol (E2)
      serum levels in supraphysiologic concentrations at the end of follicular phase. Elevated
      serum P levels leads to an accelerated endometrial maturation which interferes with the
      dialogue between embryo and endometrium. It has been reported that serum progesterone levels
      ≥ 1.5 ng/ml on the last day of COS are related to a significant decrease in the ongoing
      pregnancy rate following IVF cycles. Also, it has been reported a significant alteration in
      the endometrial gene expression profile related to P elevated levels.

      Glycodelin-A is an immunomodulatory glycoprotein synthesized by luteal-phase endometrial
      epithelium and its expression seems to be related to the action of P. Because glycodelin-A
      has immunosuppressive activity, it may facilitate the process of implantation and the
      maintenance of pregnancy.

      Objective: to evaluate the endometrial effect of Progesterone through Glycodelin-A expression
      pattern on women exposed or not to ulipristal acetate in GnRH Antagonist cycles using two
      different doses of FSH for ovarian controlled stimulation.

      Methods: prospective controlled randomized study. It will be enrolling 16 oocytes donors from
      Oocyte Donation Program of PROAR (a Reproductive Center of Rosario, Argentina). On day 3 of
      menstrual cycle FSH serum levels and antral follicular count (AFC) will be measure. If those
      results fulfill with inclusions criteria, patients will be randomize for FSH 225UI or 300UI
      GnRH-Antagonist/ urinary FSH protocol. P serum levels will be measure every 48 hours since at
      least 1 follicle ≥14 mm will be achieve until at least 1 follicle reach 19mm of diameter. The
      next day of hCG administration a new P circulating will be measure and then the patient will
      be randomize trough opaque envelopes for receive 30mg of ulipristal acetate or placebo. An
      endometrial biopsy with Cornier´s Pipelle will be performing 3 and 5 days after hCG injection
      (hCG+3 and hCG+5 days) to evaluate endometrial dating and Glycodelin-A expression pattern.

      Statistical analysis: nominal variables will be analyzing using t-Student test and the effect
      of ulipristal with ANOVA.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Glycodelin-A endometrial expression pattern and Progesterone serum levels in women expose to ulipristal acetate on stimulated ovarian cycles for FIV</measure>
    <time_frame>participants will be followed for the duration of one mesntrual cycle, from day 1 of the cycle until day 28-32</time_frame>
    <description>to evaluate Glycodelin-A expression pattern by immunohistochemistry and Progesterone serum levels on women exposed or not to ulipristal acetate in FSH/GnRH Antagonist protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>P levels during controlled ovarian stimulation since at least one follicle achieve ≥14mm of diameter</measure>
    <time_frame>participants will be followed for the duration of one mesntrual cycle,from day 1 until day 28-32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum P levels on two different doses of FSH in a GnRH Antagonist protocol for ovarian stimulation</measure>
    <time_frame>participants will be followed for the duration of one mesntrual cycle,from day 1 until day 28-32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycodelin-A endometrial expression pattern on two different doses of FSH in a GnRH Antagonist protocol for ovarian stimulation</measure>
    <time_frame>participants will be followed for the duration of one mesntrual cycle, from day 1 until day 28-32</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>UPA, 300UI FSH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients on COS with 300UI FSHu/GnRH Antagonist protocol and ulipristal acetate use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No UPA, 300FSH</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients on COS with 300UI FSHu/GnRH Antagonist protocol and without ulipristal acetate use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UPA, FSH 225</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients on COS with 225UI FSHu/GnRH Antagonist protocol and ulipristal acetate use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no UPA, FSH225</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients on COS with 225UI FSHu/GnRH Antagonist protocol and without ulipristal acetate use</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ulipristal acetate</intervention_name>
    <description>30mg of ulipristal acetate orally the day of hCG injection in a unique dose</description>
    <arm_group_label>UPA, 300UI FSH</arm_group_label>
    <other_name>UPA/FSH 300</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo orally in a unique dose the day of hCG injection</description>
    <arm_group_label>No UPA, 300FSH</arm_group_label>
    <other_name>No UPA/FSH 300</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ulipristal acetate</intervention_name>
    <description>ulipristal acetate 30mg orally in a unique dose the day of hCG administration</description>
    <arm_group_label>UPA, FSH 225</arm_group_label>
    <other_name>UPA/FSH225</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo orally in a unique dose the day of hCG injection</description>
    <arm_group_label>no UPA, FSH225</arm_group_label>
    <other_name>no UPA/FSH225</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &lt;35 years old

          -  FSH on day 3: &lt;12 UI/ml

          -  Antral follicular count ≥ 6 on day 3 of the cycle

          -  BMI: &lt;30 Kg/m2

        Exclusion Criteria:

          -  Hypothyroidism

          -  Hyperprolactinemia

          -  Kidney or liver disease

          -  Smoking

          -  Alcoholism
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Idelma Serpa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PROAR-IUNIR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Morente, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Programa de Asistencia Reproductiva de Rosario</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Idelma Serpa, MD</last_name>
    <phone>+54 0341 155668963</phone>
    <email>idelmaserpa@yahoo.com.ar</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Idelma Serpa, MD</last_name>
    <email>idelmaserpa@yahoo.com.ar</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>PROAR (Programa de Asistencia Reproductiva de Rosario</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Idelma Serpa, MD</last_name>
      <phone>+54 0341 155668963</phone>
      <email>idelmaserpa@yahoo.com.ar</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2011</study_first_submitted>
  <study_first_submitted_qc>July 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2011</study_first_posted>
  <last_update_submitted>July 19, 2011</last_update_submitted>
  <last_update_submitted_qc>July 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Idelma Serpa</name_title>
    <organization>Programa de asistencia reproductiva de rosario (PROAR)</organization>
  </responsible_party>
  <keyword>progesterone</keyword>
  <keyword>glycodelin-A</keyword>
  <keyword>ulipristal acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

